Novo Nordisk reports impressive Q4 2023 sales of DKK 65.86 billion, up 43% at CER. Explore robust growth in Diabetes and Obesity care, including GLP-1 diabetes and Wegovy. CEO anticipates continued success in 2024 with sales growth of 18%-26% .
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.
Stryker Corp (NYSE: SYK) shares are trading higher in Tuesday's after-hours session after the company reported better-than-expected fourth-quarter financial results.
Danaher reported Q4 2023 adjusted EPS of $2.09, exceeding consensus of $1.89. Sales decreased 10% Y/Y to $6.4B. Non-GAAP core revenue declined 11.5%. Guidance for core revenue growth will continue, but not for base business core revenue.
HCA Healthcare surpasses Q4 2023 revenue expectations at $17.30B. CEO Sam Hazen highlights strong demand, increased ER visits, and improved financial performance. Mike Marks appointed as new CFO.